Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
RMC-9805 by Revolution Medicines for Pancreatic Ductal Adenocarcinoma: Likelihood of Approval
RMC-9805 is under clinical development by Revolution Medicines and currently in Phase I for Pancreatic Ductal Adenocarcinoma. According to GlobalData,...
Data Insights
Risk adjusted net present value: What is the current valuation of Revolution Medicines's RMC-9805?
RMC-9805 is a small molecule commercialized by Revolution Medicines, with a leading Phase I program in Colorectal Cancer. According to...